Patients | Age | Duration to diagnosis (months) | screening test | MMG positive | USG positve | Procedure | Pathology | Stage | Positivity of hormone receptor | Recurrence | Status | Follow-up duration |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 59 | 343 | + | + | + | CS | solid-tubular carcinoma | 1 | ER(−),PR(−),HE2(+) | - | Alive | 79 |
2 | 56 | 262 | + | + | + | CS | solid-tubular carcinoma | 1 | N/A | - | Dead | 56 |
3 | 58 | 270 | + | + | + | CS | non invasive ductal carcinoma | 0 | ER(−),PR(−),HE2(+) | - | Alive | 69 |
4 | 46 | 66 | - | - | - | MRM | solid-tubular carcinoma | 1 | ER(−) | - | Alive | 187 |
5 | 42 | 57 | + | + | + | CS | papillotubular carcinoma | 1 | HE2(+) | - | Alive | 142 |
6 | 48 | 48 | + | - | + | CS | papillotubular carcinoma | 1 | ER(+),PR(−),HE2(−) | - | Alive | 113 |
7 | 41 | 113 | + | + | + | CS | solid-tubular carcinoma | 1 | ER(+),PR(−),HE2(+) | - | Alive | 24 |
8 | 35 | 80 | + | - | + | CS | papillotubular carcinoma | 0 | ER(+),PR(+),HE2(+) | - | Alive | 43 |
9 | 44 | 99 | + | + | + | MRM | non invasive ductal carcinoma | 2A | ER(+),PR(+),HE2(+) | - | Alive | 5 |